Dr. Gregory Piazza, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Massachusetts Medical School (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,182
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Massachusetts Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MA license 217298
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- North Shore Medical Center - Salem, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- Brigham and Womens Physicians Organization Inc (2,994 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,182
- Services billed
- 1,503
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 948 | 763 |
| Established patient office or other outpatient visit, 40-54 minutes | 262 | 212 |
| New patient office or other outpatient visit, 60-74 minutes | 79 | 79 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 69 | 69 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 68 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 57 | 40 |
| Established patient office or other outpatient visit, 30-39 minutes | 32 | 29 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 72 payments worth $103,222 in total to this clinician.
| Boston Scientific Corporation | $78,602 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $10,689 |
| Pfizer Inc. | $6,125 |
| Regeneron Pharmaceuticals, Inc. | $5,406 |
| Penumbra, Inc. | $2,400 |
| Consulting Fee | $56,186 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $29,700 |
| Travel and Lodging | $14,313 |
| Food and Beverage | $2,723 |
| Grant | $300 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boston Scientific Corporation Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) General - Therapies · General - Therapies_PI | $11,900 |
| Boston Scientific Corporation Jan 11, 2025 | Travel and Lodging General - Therapies · General - Therapies_PI · travel to BOSTON, MA · in-kind | $9,949 |
| E.r. Squibb & Sons, L.l.c. Oct 27, 2025 | Consulting Fee | $9,281 |
| Boston Scientific Corporation Sep 18, 2025 | Consulting Fee General - Therapies · General - Therapies_PI | $9,100 |
| Boston Scientific Corporation May 1, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $7,811 |
| Boston Scientific Corporation Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) General - Therapies · General - Therapies_PI | $5,600 |
| Pfizer Inc. Mar 5, 2025 | Consulting Fee ELIQUIS · CARDIOVASCULAR;METABOLIC DISEASE | $5,125 |
| Boston Scientific Corporation Dec 11, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $3,938 |
| Boston Scientific Corporation Jul 24, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $3,206 |
| Boston Scientific Corporation Mar 6, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $2,813 |
All 51 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Penumbra, Inc. Dec 19, 2025 | Consulting Fee Indigo System · Peripheral Intervention | $600 |
| Boston Scientific Corporation Dec 11, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $3,938 |
| Boston Scientific Corporation Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) EkoSonic · EkoSonic_PI | $2,800 |
| Boston Scientific Corporation Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) EkoSonic · EkoSonic_PI | $1,050 |
| Boston Scientific Corporation Nov 11, 2025 | Travel and Lodging EkoSonic · EkoSonic_PI · travel to Boston, MA · in-kind | $500 |
| E.r. Squibb & Sons, L.l.c. Oct 29, 2025 | Travel and Lodging travel to ANAHEIM, CA | $201 |
| E.r. Squibb & Sons, L.l.c. Oct 27, 2025 | Consulting Fee | $9,281 |
| Boston Scientific Corporation Oct 16, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $1,256 |
| E.r. Squibb & Sons, L.l.c. Oct 4, 2025 | Travel and Lodging travel to Anaheim, CA | $797 |
| E.r. Squibb & Sons, L.l.c. Oct 4, 2025 | Travel and Lodging travel to Anaheim, CA | $201 |
| Boston Scientific Corporation Sep 18, 2025 | Consulting Fee General - Therapies · General - Therapies_PI | $9,100 |
| Boston Scientific Corporation Sep 18, 2025 | Consulting Fee General - Therapies · General - Therapies_PI | $2,100 |
| Boston Scientific Corporation Sep 18, 2025 | Consulting Fee General - Therapies · General - Therapies_PI | $1,000 |
| Boston Scientific Corporation Aug 21, 2025 | Travel and Lodging JETSTREAM SC · JETSTREAM_PI · travel to Minneapolis, MN · in-kind | $597 |
| Boston Scientific Corporation Aug 21, 2025 | Travel and Lodging JETSTREAM SC · JETSTREAM_PI · travel to Minneapolis, MN · in-kind | $344 |
| Penumbra, Inc. Jul 30, 2025 | Consulting Fee Indigo System · Peripheral Intervention | $1,200 |
| Regeneron Pharmaceuticals, Inc. Jul 25, 2025 | Consulting Fee | $1,577 |
| Regeneron Pharmaceuticals, Inc. Jul 25, 2025 | Consulting Fee | $901 |
| Regeneron Pharmaceuticals, Inc. Jul 25, 2025 | Consulting Fee | $225 |
| Boston Scientific Corporation Jul 24, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $3,206 |
| Boston Scientific Corporation Jun 20, 2025 | Compensation for services other than consulting (speaking, faculty) General - Therapies · General - Therapies_PI | $1,750 |
| Boston Scientific Corporation Jun 20, 2025 | Compensation for services other than consulting (speaking, faculty) General - Therapies · General - Therapies_PI | $350 |
| Boston Scientific Corporation Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) General - Therapies · General - Therapies_PI | $11,900 |
| Boston Scientific Corporation Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) General - Therapies · General - Therapies_PI | $5,600 |
| Boston Scientific Corporation Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) EkoSonic · EkoSonic_PI | $1,400 |
| Boston Scientific Corporation Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) EkoSonic · EkoSonic_PI | $1,050 |
| Boston Scientific Corporation Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) General - Therapies · General - Therapies_PI | $1,000 |
| Boston Scientific Corporation Jun 12, 2025 | Travel and Lodging General - Therapies · General - Therapies_PI · travel to Nashville, TN | $103 |
| Boston Scientific Corporation May 22, 2025 | Grant General - Therapies · General - Therapies_PI | $300 |
| Boston Scientific Corporation May 15, 2025 | Compensation for services other than consulting (speaking, faculty) EkoSonic · EkoSonic_PI | $1,400 |
| Boston Scientific Corporation May 1, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $7,811 |
| Boston Scientific Corporation Apr 26, 2025 | Travel and Lodging General - Vascular Intervention · General - Vascular Intervention_PI · travel to Nashville, TN · in-kind | $338 |
| Boston Scientific Corporation Apr 25, 2025 | Travel and Lodging General - Vascular Intervention · General - Vascular Intervention_PI · travel to Nashville, TN · in-kind | $375 |
| Boston Scientific Corporation Apr 24, 2025 | Travel and Lodging General - Vascular Intervention · General - Vascular Intervention_PI · travel to Nashville, TN · in-kind | $210 |
| Regeneron Pharmaceuticals, Inc. Apr 4, 2025 | Consulting Fee | $901 |
| Penumbra, Inc. Apr 4, 2025 | Consulting Fee Indigo System · Peripheral Intervention | $600 |
| Boston Scientific Corporation Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) General - Therapies · General - Therapies_PI | $1,050 |
| Boston Scientific Corporation Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) General - Therapies · General - Therapies_PI | $350 |
| Boston Scientific Corporation Mar 20, 2025 | Consulting Fee General - Therapies · General - Therapies_PI | $1,400 |
| Boston Scientific Corporation Mar 20, 2025 | Consulting Fee General - Therapies · General - Therapies_PI | $350 |
| Boston Scientific Corporation Mar 6, 2025 | Consulting Fee Clinical Trial Product · Clinical Trial Product_PI | $2,813 |
| Pfizer Inc. Mar 5, 2025 | Consulting Fee ELIQUIS · CARDIOVASCULAR;METABOLIC DISEASE | $5,125 |
| Pfizer Inc. Mar 5, 2025 | Consulting Fee ELIQUIS · CARDIOVASCULAR;METABOLIC DISEASE | $1,000 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee | $901 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee | $901 |
| Boston Scientific Corporation Feb 6, 2025 | Travel and Lodging EkoSonic · EkoSonic_PI · travel to BOSTON, MA | $123 |
| Boston Scientific Corporation Jan 13, 2025 | Travel and Lodging General - Therapies · General - Therapies_PI · travel to BOSTON, MA · in-kind | $181 |
| Boston Scientific Corporation Jan 13, 2025 | Travel and Lodging General - Therapies · General - Therapies_PI · travel to BOSTON, MA · in-kind | $27.75 |
| Boston Scientific Corporation Jan 12, 2025 | Travel and Lodging General - Therapies · General - Therapies_PI · travel to BOSTON, MA · in-kind | $158 |
| Boston Scientific Corporation Jan 11, 2025 | Travel and Lodging General - Therapies · General - Therapies_PI · travel to BOSTON, MA · in-kind | $9,949 |
| Boston Scientific Corporation Jan 11, 2025 | Travel and Lodging General - Therapies · General - Therapies_PI · travel to BOSTON, MA · in-kind | $209 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $787,261 in research payments for these studies, mostly to the institutions running them.
- Provider- and Patient-Facing Alert-Based Computerized Decision Support for Identification and Management of Patients with Familial Hypercholesterolemia (FH-ALERT Trial)
Regeneron Pharmaceuticals, Inc. - A Clinical Study of patients with PE Receiving Anticoagulation Alone and a Similar Analysis of the OPTALYSE-PE Trial
Boston Scientific Corporation - Extended-Duration Low-Dose Apixaban to Prevent Recurrence in Provoked Venous Thromboembolism
E.r. Squibb & Sons, L.l.c. - A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
Regeneron Pharmaceuticals, Inc. · Completed · NCT06299111
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.